Topic: endometrial cancer
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
Merck and Eisai are out with the expanded data that recently snagged their Keytruda-Lenvima combo three endometrial cancer go-aheads.
Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.